Abstracts tagged "mouse model and osteoclasts"

Abstract Number: 1100 • 2016 ACR/ARHP Annual Meeting
Tenofovir, a Nucleoside Analog Reverse Transcriptase Inhibitor for Treatment of HIV, Promotes Osteoclast Differentiation and Decreases Osteoblast Formation By a Mechanism Depending on ATP Release and Adenosine
Aranzazu Mediero^1,2, Patricia Llamas³, Sergio Portal-Nuñez⁴, Raquel Largo⁵, Gabriel Herrero-Beaumont⁵ and Bruce Cronstein⁶, ¹Medicine, Divison of Translational Medicine, NYU School of Medicine, New York City, NY, ²Bone and Joint Research Unit, Fundación Jiménez Díaz UAM, Madrid, Spain, ³Bone and Joint Research Unit, IIS-Fundacion Jimenez Díaz UAM, Madrid, Spain, ⁴Bone and Joint Research Unit, IIS-Fundación Jimenez Días UAM, Madrid, Spain, ⁵Bone and Joint Research Unit, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain, ⁶Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: Human Immunodeficiency Virus (HIV) infection devastates the immune system but also affects tissues and organs such as kidney, liver, central nervous system, heart and…
Abstract Number: 1140 • 2015 ACR/ARHP Annual Meeting
Resident Non-Classical Monocytes Are Critically Important for Tissue Destruction in Arthritis
Antonia Puchner¹, Victoria Saferding², Eliana Goncalves-Alves³, Michael Bonelli³, Silvia Hayer⁴, Carl-Walter Steiner², Birgit Niederreiter⁵, Josef S. Smolen¹, Kurt Redlich³ and Stephan Blüml³, ¹Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Rheumatology, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁵Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: Bone destruction in rheumatoid arthritis is mediated by osteoclasts, which are derived from precursor cells of the myeloid lineage. Although there is much known…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].